Us Bancorp \De\ Arcus Biosciences, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 272 shares of RCUS stock, worth $4,216. This represents 0.0% of its overall portfolio holdings.

Number of Shares

272

Previous 2,062 86.81%

Holding current value

$4,216

Previous $31,000 87.1%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$13.69 - $18.01 $24,505 - $32,237	-1,790 Reduced 86.81%	272 $4,000
Q2 2024 Aug 06, 2024	BUY	$14.59 - $18.48 $19,740 - $25,003	1,353 Added 190.83%	2,062 $31,000
Q1 2024 May 07, 2024	SELL	$14.83 - $20.18 $117,928 - $160,471	-7,952 Reduced 91.81%	709 $13,000
Q4 2023 Feb 09, 2024	BUY	$13.43 - $19.63 $90,665 - $132,522	6,751 Added 353.46%	8,661 $165,000
Q3 2023 Nov 03, 2023	SELL	$17.62 - $23.54 $17 - $23	-1 Reduced 0.05%	1,910 $34,000
Q2 2023 Aug 09, 2023	BUY	$16.97 - $22.03 $9,095 - $11,808	536 Added 38.98%	1,911 $38,000
Q1 2023 May 09, 2023	BUY	$15.96 - $23.15 $5,234 - $7,593	328 Added 31.33%	1,375 $25,000
Q4 2022 Feb 13, 2023	BUY	$19.7 - $35.71 $10,775 - $19,533	547 Added 109.4%	1,047 $21,000
Q3 2022 Oct 27, 2022	BUY	$23.23 - $30.07 $720 - $932	31 Added 6.61%	500 $13,000
Q2 2022 Aug 01, 2022	SELL	$17.23 - $37.73 $1,705 - $3,735	-99 Reduced 17.43%	469 $12,000
Q1 2022 May 11, 2022	BUY	$28.92 - $41.83 $8,010 - $11,586	277 Added 95.19%	568 $18,000
Q4 2021 Feb 11, 2022	SELL	$31.38 - $48.47 $7,907 - $12,214	-252 Reduced 46.41%	291 $12,000
Q3 2021 Nov 10, 2021	BUY	$26.93 - $37.68 $11,956 - $16,729	444 Added 448.48%	543 $19,000
Q4 2020 Feb 04, 2021	BUY	$17.0 - $32.36 $1,683 - $3,203	99 New	99 $3,000
Q3 2020 Nov 10, 2020	SELL	$17.14 - $25.47 $754 - $1,120	-44 Closed	0 $0
Q2 2020 Aug 07, 2020	BUY	$13.97 - $36.56 $614 - $1,608	44 New	44 $1,000
Q3 2019 Nov 08, 2019	SELL	$6.44 - $10.18 $18,618 - $29,430	-2,891 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$8.95 - $12.49 $5,772 - $8,056	645 Added 28.72%	2,891 $36,000
Q4 2018 Feb 13, 2019	BUY	$9.74 - $14.5 $1,168 - $1,740	120 Added 5.64%	2,246 $25,000
Q3 2018 Nov 01, 2018	BUY	$10.88 - $14.95 $23,130 - $31,783	2,126 New	2,126 $30,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account